Avricore Health INC. (AVCRF) — SEC Filings

Q: What are the key financial highlights for Avricore Health INC.?

Key financial highlights for Avricore Health INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Avricore Health INC.?

Key executives at Avricore Health INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Avricore Health INC. stock?

Risk factors for Avricore Health INC. (AVCRF) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Avricore Health INC.?

Forward-looking statements and predictions from Avricore Health INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Avricore Health INC.. Recent 6-K filing on Dec 10, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Avricore Health INC. on SEC EDGAR

Overview

Avricore Health INC. (AVCRF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 10, 2025: Avricore Health Inc. filed a Form 6-K on December 10, 2025, for the reporting period ending November 30, 2025. The company, formerly known as Vanc Pharmaceuticals Inc., NUVA Pharmaceuticals Inc., and ALDA Pharmaceuticals Corp., is based in Vancouver, BC. This filing is a report of a foreign private

Sentiment Summary

Across 15 filings, the sentiment breakdown is: 1 bearish, 14 neutral. The dominant filing sentiment for Avricore Health INC. is neutral.

Filing Type Overview

Avricore Health INC. (AVCRF) has filed 13 6-K, 2 20-F with the SEC between May 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (15)

Avricore Health Inc. Files November 2025 6-K Report — 6-K · Dec 10, 2025 Risk: low
Avricore Health Inc. filed a Form 6-K on December 10, 2025, for the reporting period ending November 30, 2025. The company, formerly known as Vanc Pharmaceutica
Avricore Health Inc. Files August 2025 6-K Report — 6-K · Sep 15, 2025 Risk: low
Avricore Health Inc. filed a Form 6-K for the month of August 2025, reporting as a foreign private issuer. The company, formerly known as Vanc Pharmaceuticals I
Avricore Health Inc. Files July 2025 6-K Report — 6-K · Aug 8, 2025 Risk: low
Avricore Health Inc. filed a Form 6-K on August 8, 2025, for the month of July 2025. The company, formerly known as Vanc Pharmaceuticals Inc., NUVA Pharmaceutic
Avricore Health Inc. Files June 2025 6-K Report — 6-K · Jul 11, 2025 Risk: low
Avricore Health Inc. filed a Form 6-K for the month of June 2025, reporting as a foreign private issuer. The company, formerly known as Vanc Pharmaceuticals Inc
Avricore Health's Net Loss Widens 59% Amidst Capital Raises — 20-F · Jun 16, 2025 Risk: high
Avricore Health Inc. reported a net loss of $1,677,000 for the fiscal year ended December 31, 2024, a significant increase from the net loss of $1,053,000 in 20
Avricore Health Inc. Files May 2025 6-K Report — 6-K · Jun 5, 2025 Risk: low
Avricore Health Inc. filed a Form 6-K for the month of May 2025, reporting as a foreign private issuer. The company, formerly known as Vanc Pharmaceuticals Inc.
Avricore Health Inc. Files April 2025 6-K Report — 6-K · May 20, 2025 Risk: low
Avricore Health Inc. filed a Form 6-K on May 20, 2025, for the month of April 2025. The company, formerly known as Vanc Pharmaceuticals Inc., NUVA Pharmaceutica
Avricore Health Inc. Files January 2025 6-K Report — 6-K · Feb 6, 2025 Risk: low
Avricore Health Inc. filed a Form 6-K on February 6, 2025, for the month of January 2025. The company, formerly known as Vanc Pharmaceuticals Inc., NUVA Pharmac
Avricore Health Inc. Files November 2024 6-K Report — 6-K · Dec 5, 2024 Risk: low
Avricore Health Inc. filed a Form 6-K for the month of November 2024, reporting as a foreign private issuer. The company, formerly known as Vanc Pharmaceuticals
Avricore Health Inc. Files September 2024 6-K Report — 6-K · Oct 7, 2024 Risk: low
Avricore Health Inc. filed a Form 6-K on October 7, 2024, for the month of September 2024. The company, formerly known as Vanc Pharmaceuticals Inc. and NUVA Pha
Avricore Health Inc. Files August 2024 6-K Report — 6-K · Sep 6, 2024 Risk: low
Avricore Health Inc. filed a Form 6-K on September 6, 2024, for the reporting period ending August 31, 2024. The company, formerly known as Vanc Pharmaceuticals
Avricore Health Inc. Files 6-K Report — 6-K · Jul 9, 2024 Risk: low
Avricore Health Inc. filed a Form 6-K on July 9, 2024, for the reporting period ending June 30, 2024. The company, formerly known as Vanc Pharmaceuticals Inc.,
Avricore Health Inc. Files May 2024 6-K Report — 6-K · Jun 20, 2024 Risk: low
Avricore Health Inc. filed a Form 6-K on June 20, 2024, for the month ending May 31, 2024. The company, formerly known as Vanc Pharmaceuticals Inc., NUVA Pharma
Avricore Health Inc. Files 20-F for FY2023 — 20-F · Jun 12, 2024 Risk: medium
Avricore Health Inc. filed its 20-F form for the fiscal year ending December 31, 2023. The company, formerly known as Vanc Pharmaceuticals Inc., NUVA Pharmaceut
Avricore Health Inc. Files April 2024 6-K Report — 6-K · May 8, 2024 Risk: low
Avricore Health Inc. filed a Form 6-K for the month of April 2024, reporting as a foreign private issuer. The company, formerly known as Vanc Pharmaceuticals In

Risk Profile

Risk Assessment: Of AVCRF's 15 recent filings, 1 were flagged as high-risk, 1 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Industry Context

Avricore Health Inc. operates within the pharmaceutical preparations sector (SIC 2834). This industry is characterized by significant research and development costs, stringent regulatory oversight, and a competitive landscape driven by innovation and market access. Companies in this space often require substantial capital to fund product development and commercialization.

Top Tags

foreign-private-issuer (10) · reporting (6) · company-update (5) · 6-K (4) · regulatory-filing (4) · sec-filing (3) · corporate-update (2) · 6-k (2) · filing (1) · corporate-history (1)

Key Numbers

Net Loss: $1.68M — Increased by 59.26% from $1.05M in 2023 to $1.68M in 2024.
Accumulated Deficit: $35.86M — Grew from $34.18M in 2023 to $35.86M in 2024, indicating persistent losses.
Issued Capital: $40.30M — Increased from $39.65M in 2023 to $40.30M in 2024, suggesting equity financing.
Warrant Reserve: $1.10M — Increased from $1.01M in 2023 to $1.10M in 2024, reflecting warrant issuances.
Increase in Net Loss: 59.26% — Percentage increase in net loss from 2023 to 2024.
Commission File Number: 000-51848 — Identifies the SEC filing
Filing Date: 20250520 — Indicates the date the report was submitted to the SEC.
Reporting Period End Date: 20250430 — Specifies the end date of the period covered by the report.
Fiscal Year End: 2023-12-31 — Reporting period for the 20-F filing.

Related Companies

AVRX · AVCR

Frequently Asked Questions

What are the latest SEC filings for Avricore Health INC. (AVCRF)?

Avricore Health INC. has 15 recent SEC filings from May 2024 to Dec 2025, including 13 6-K, 2 20-F. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of AVCRF filings?

Across 15 filings, the sentiment breakdown is: 1 bearish, 14 neutral. The dominant sentiment is neutral.

Where can I find Avricore Health INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Avricore Health INC. (AVCRF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Avricore Health INC.?

Financial highlights for Avricore Health INC. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for AVCRF?

The investment thesis for AVCRF includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Avricore Health INC.?

Executive information for Avricore Health INC. is extracted from SEC filings as they are enriched with AI analysis.

What are the main risk factors for Avricore Health INC. stock?

Of AVCRF's 15 assessed filings, 1 were flagged high-risk, 1 medium-risk, and 13 low-risk.

What are recent predictions and forward guidance from Avricore Health INC.?

Forward guidance and predictions for Avricore Health INC. are extracted from SEC filings as they are enriched.